Senti Bio Signs Lease Agreement and Begins Design of Clinical and Commercial-Scale Manufacturing Facility for Allogeneic CAR-NK Cell Therapies - 92,000 square-foot cGMP facility will be designed to support clinical and commercial-scale production of allogeneic CAR-NK cell pipeline - - Facility to initially focus on preclinical product...